Co-infection of influenza A and B viruses (IAV and IBV) results in marked decreases in IAV replication. Multiple mechanisms have been proposed for this phenomenon. Recently, we reported that IBV nucleoprotein (BNP) alone can suppress IAV replication and proposed an inhibition model in which BNP binds IAV nucleoprotein (ANP) and disrupts IAV polymerase complexes. Here, using mutagenesis and co-immunoprecipitation, we determined the protein motifs mediating the intertypic ANP-BNP complex and showed that it specifically interferes with ANP's interaction with the PB2 subunit of the IAV polymerase but not with the other subunit PB1. We further demonstrated that BNP only suppresses growth of IAVs but not other RNA viruses. However, different IAV strains display varied sensitivity toward the BNP's inhibitory effect. Together, our data provide mechanistic insights into intertypic nucleoprotein complex formation and highlight the role of BNP as a potential broad-spectrum anti-IAV agent.
Introduction
Type A and B influenza viruses (IAV and IBV) are morphologically indistinguishable and possess similarly-organized eight-segmented RNA genomes that encode similar sets of proteins (Ruigrok et al., 1984; Palese and Shaw, 2006) . Despite their close phylogenic relationship, IAV and IBV have not generated natural or synthetic intertypic reassortants upon co-infection (Tobita and Ohori, 1979; Iwatsuki-Horimoto et al., 2008) . Moreover, IBV can substantially inhibit growth of IAV. These phenomena, collectively termed intertypic interference, were first reported in 1954 (Gotlieb and Hirst, 1954) and have since been confirmed in numerous strains of IAV and IBV (Tobita and Ohori, 1979; Mikheeva and Ghendon, 1982; Kaverin et al., 1983; Aoki et al., 1984) . Several mechanisms have been proposed for intertypic interference. Initial works identified primary transcription as the point where interference occurs, leading to a steep decline in viral protein synthesis (Mikheeva and Ghendon, 1982; Aoki et al., 1984) . Ill-matched binding between the non-coding regions of some viral RNA (vRNA) segments and the polymerase complexes from different types of influenza viruses could also prevent intertypic genetic reassortment (Muster et al., 1991; Baker et al., 2014) . More recent studies reported incompatibility between IAV and IBV polymerase subunits, resulting in inefficient intertypic polymerase complexes and reduced vRNA production (Iwatsuki-Horimoto et al., 2008; Wunderlich et al., 2010) . These mechanisms are not mutually exclusive, and they all pointed to the viral polymerase complex as a critical factor in intertypic interference.
For both IAV and IBV, the polymerase complex is bound at the end of each vRNA segment and consists of three protein subunits: polymerase basic 1 and 2 (PB1 and PB2) and polymerase acidic (PA) (Klumpp et al., 1997; Coloma et al., 2009; Arranz et al., 2012) . The rest of the vRNA strand is encapsidated by multimers of nucleoproteins (NP), primarily formed by insertion of the Cterminal 'tail loop' of one NP molecule into the next (Pons et al., 1969; Ye et al., 2006; Ng et al., 2008 Ng et al., , 2012 . The region that surrounds and donates interaction sites to the tail loop comprises discontinuous portions of NP and will be collectively called the 'tail-loop receptor' for short. An example of these critical tail looptail-loop receptor interactions is the highly conserved salt bridge between R472 and E395 (BNP numbering) ( Fig. 1A ; Ng et al., 2012) .
Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/yviro Additional aromatic residues on the tail loop such as F468 also contribute important van der Waal interactions. Recent studies have also implicated the role of phosphorylation in regulating NP multimerization (Turrell et al., 2015; Mondal et al., 2015) . Although high-resolution details are still lacking, biochemical experiments and cryo-electron microscopy have suggested that NP interacts with PB1 and PB2 within the viral ribonucleoprotein (vRNP) complexes (Arranz et al., 2012; Biswas et al., 1998) . Moreover, NP performs multiple functions, including nuclear import and export of vRNA and regulation of transcription and replication, by interacting with several partner proteins of both viral and cellular origins (Biswas et al., 1998; Portela and Digard, 2002; Shapiro and Krug, 1988; Cao et al., 2014) . As per these crucial roles, NP has been a prime target for cellular antiviral mechanisms along with influenza antiviral drug research (Verhelst et al., 2012; Turan et al., 2004) ).
Recently, we have suggested that IAV nucleoprotein (ANP) is also a target of a novel antiviral mechanism mediated by its close cousin, IBV nucleoprotein (BNP) (Wanitchang et al., 2012; Jaruampornpan et al., 2014) . First, we observed suppressed IAV polymerase activity and a moderate reduction in IAV replication in the presence of BNP (Wanitchang et al., 2012) . Based on Myc antibody and FITC-conjugated goat-anti-mouse antibody. Scale bar, 10 μm. IBV polymerase activity was determined by minigenome assay as described in section Materials and Methods. Values are average7 S.D. and are relative to wild-type BNP. (C) IAV polymerase inhibition assay was performed as described in section Materials and Methods. Values are relative to IAV polymerase activity in the presence of the pHW2000 vector (lane '-'). Error bars indicate S.D. of three independent experiments. (D) Co-IP with anti-ANP antibody was performed on lysates prepared from HEK293T cells transfected with pHW2000 plasmids expressing ANP and BNP (WT or mutants; 500 ng each). IP, immunoprecipitate complex; input, 10% of the input lysate. (E) Concentration dependence of BNP inhibitory effects was performed with varying amount of pHW2000-BNP-WT (black) or E395A (gray) in IAV minigenome assay as described in section Materials and Methods.
biochemical evidence, we further suggested that BNP inhibits IAV polymerase activity by non-functionally interacting with ANP and interfering with vRNP complex formation (Jaru-ampornpan et al., 2014) . However, many mechanistic questions still remain. Do heterotypic ANP-BNP interaction require the same set of interactions mediating homotypic NP oligomers? Does BNP disrupt ANP's interactions with both PB1 and PB2? How does BNP compete with polymerase subunit(s) for ANP? More importantly, potency and specificity of BNP's antiviral effect have yet to be rigorously examined. These details will augment our understanding of BNP's virus suppression mechanism and will be important for its potential use as an antiviral agent.
In this work, we present evidence that BNP homo-oligomerization motifs are necessary for its inhibitory effect most likely through their involvement in heterotypic NP binding. We showed that BNP can disrupt the ANP-PB2 interaction but does not interfere with PB1 binding in the absence of other polymerase subunits. Lastly, we demonstrated that BNP potently and specifically inhibits growth of different IAV strains. Together, these results shed new mechanistic light on our understanding of intertypic interference mediated by BNP and provide knowledge basis for future manipulation of BNP for anti-IAV use.
Results

Tail loop and tail-loop receptor of BNP are critical for ANP binding and IAV polymerase inhibition
In previous work, we showed that nuclear localization and RNA-binding motifs are important for BNP's inhibitory effect (Jaruampornpan et al., 2014) . In this work, we explored if and how oligomerization ability of BNP was necessary for its inhibitory effect on IAV polymerase. We studied three representative BNP oligomerization mutants. R472A and F468S are located in the tail loop, whereas E395A represents a tail-loop receptor mutant (Fig. 1A) . These mutants severely impaired BNP oligomerization and IBV polymerase activity (Ng et al., 2012) . We asked if they still inhibited IAV polymerase. We first confirmed that all BNP variants are normally localized to the nucleus (Fig. 1B) . Then, using IAV minigenome assay, we showed that BNP-R472A and BNP-F468S had no effect, while BNP-E395A displayed a reduced inhibitory effect on IAV polymerase activity (Fig. 1C) .
We asked whether these residues, especially those in the tail loop, are required for IAV polymerase inhibition because they are utilized in intertypic NP oligomerization. To test this, cell lysates prepared from HEK293T cells transfected with a pair of plasmids encoding ANP and each of the BNP variants were coimmunoprecipitated by anti-ANP. The tail loop mutants, R472A and F468S, displayed marked decreases in ANP binding, correlating with their inability to suppress IAV polymerase activity (Fig. 1D ). These data suggest that BNP utilizes interactions from the tail loop in both homo-and heterotypic oligomerization.
Interestingly, BNP-E395A also showed absence of ANP interaction in our co-immunoprecipitation conditions but still retained some, albeit substantially reduced, inhibitory effect ( Fig. 1D and C) . This is a surprising outlier to our previous inhibition model (Jaru-ampornpan et al., 2014) , implying a possibility in which a 'non-interacting' BNP could somehow interrupt the IAV polymerase complex. Nevertheless, the lingering effect of BNP-E395A exhibited concentration dependence similarly displayed by wildtype BNP but with much smaller magnitudes, suggesting that BNP-E395A inhibits IAV polymerase possibly through a competitive mechanism similar to wild-type BNP but much less efficiently (Fig. 1E) . Although not definitively, this observation argues for weak or transient interaction between BNP-E395A and ANP that may be undetectable by our current binding assay but still results in IAV polymerase inhibition (more in section Discussion).
The outlying behavior of BNP-E395A prompted us to further interrogate our original hypothesis that the intertypic NP complex underlies BNP's inhibitory effect. To this end, we made additional novel mutations around the tail loop-tail loop receptor interface to test whether there is a correlation between ANP binding and the IAV polymerase inhibitory effect. D380 and G391 cap each end of the helix adjacent to the crucial E395 loop, whereas P444 and R447 reside in the loop that folds around the tail loop on the opposite side ( Fig. 2A , left and right panels respectively; Ng et al., 2012) . G431 is situated on the base of a small β-strand further away and does not seem to participate in homo-oligomerization (Ng et al., 2012) and was chosen as a control. We confirmed that these residues were not variations between IBV strains, as they were conserved among 1912 available BNP sequences from the influenza virus resource database (Bao et al., 2008) .
These BNP mutants are nuclear localized but differentially affect IBV polymerase activity (Fig. 2B ). While G431A mutation increases IBV polymerase activity by almost two-fold, others showed defects in IBV polymerase activity ranging from 80% reduction in the case of R447A to almost no activity in others (Fig. 2B) . Next, we performed IAV minigenome assays in the presence of the plasmid expressing each BNP variant. D380A and G391A showed almost no inhibitory effect on IAV polymerase (Fig. 2C ). These BNP mutants were barely observed in a pulldown by anti-ANP, suggesting significant decreases in ANP binding (Fig. 2D) . Mutations on the opposite side of the tail-loop receptor showed variations in their abilities to inhibit IAV polymerase and to interact with ANP ( Fig. 2C and D) . While G431A and R447A exhibited wild-type level of inhibition, P444A could hardly inhibit IAV polymerase (Fig. 2C ). Co-immunoprecipitation results reflected the trend observed in polymerase inhibition; P444A showed no ANP binding, in contrast to strong ANP binding observed with wild-type, G431A and R447A BNP (Fig. 2D) . Together, these results revealed additional residues in BNP's tailloop receptor that are essential for intertypic NP interactions and IAV polymerase inhibition. With the exception of E395A, these mutants, along with those from the above section and the previous report (Jaru-ampornpan et al., 2014) , displayed a strong correlation between ANP binding and IAV polymerase inhibition.
Phosphorylation of BNP do not abolish heterotypic NP complex formation
Recent work has identified phosphorylation sites for influenza virus nucleoproteins and demonstrated that phosphorylation is an important regulator of nucleoprotein oligomerization (Turrell et al., 2015; Mondal et al., 2015) . Phosphomimetic mutations in BNP (S226D or S463D) disrupt BNP's tail loop-tail-loop receptor interactions and attenuated IBV replication (Mondal et al., 2015) . To test phosphorylation's effect on heterotypic NP complex formation, we mutated these two critical serines, S226 and S463, to aspartate to mimic the phosphorylated state of BNP. Both BNP-S226D and BNP-S463D are localized in the nucleus (Fig. 3A) . BNP-S463D showed reduced IBV polymerase activity, while the effect of the S226D mutation was more pronounced (Fig. 3A) . These results are consistent with the observations that recombinant IBVs containing the S463D mutation showed attenuated growth while that containing the S226D could not be rescued (Mondal et al., 2015) .
Interestingly, BNP-S226D and BNP-S463D caused substantial reduction of IAV polymerase activity (Fig. 3B ). Co-immunoprecipitation by anti-ANP antibody revealed that both BNP mutants could be observed in the elution, suggesting that they could interact with ANP (Fig. 3C ).
This was perhaps surprising in light of recent characterization of these mutants as defective in homotypic oligomerization (Mondal et al., 2015) . Nevertheless, the results in this part further support the notion that the ANP-BNP interaction is critical for IAV polymerase inhibitory effect of BNP.
BNP timing and expression level determine magnitude of its effect on IAV growth suppression
We next evaluated the effect of the intertypic NP complex in viral infection contexts. For precise control, we chose to use a non- interacting BNP mutant as a baseline for comparison. Since all these mutants disable IBV polymerase, rescuing mutant IBV particles for co-infection experiment was impossible. To circumvent this problem, we turned to a PB2-knockout IAV system that allows expression of a foreign protein (Uraki et al., 2013) . Briefly, the PB2 coding sequence in the PR8 virus was replaced with BNP (wild-type or mutants) coding sequences. Reverse genetics was performed to generate rgΔPB2-PR8-BNP IAVs encoding both ANP and BNP (Fig. 4A ). Modified MDCK cells expressing PB2 (MDCK-PB2) were infected with these chimeric viruses, and BNP expression in infected cell extracts was confirmed (Fig. 4B ).
To analyze viral growth, MDCK-PB2 cells were infected with chimeric IAVs harboring different BNP variants (MOI ¼0.001), and infectious viral progenies in supernatants were quantified by plaque assay. As a control, the growth of ΔPB2-PR8-mCherry, the chimeric virus harboring the mCherry gene, was analyzed in parallel. Barely one-log difference in growth was observed between ΔPB2-PR8-BNP and ΔPB2-PR8-mCherry, and growths of other chimeric viruses were in-between (Fig. 4B ). This small effect is reminiscent of a moderate suppression of IAV growth seen in MDCK cells transduced by pseudotyped retrovirus expressing BNP in previous work (Wanitchang et al., 2012) . Still, this is surprising, considering how largely IAV polymerase activity was reduced by BNP protein in in vitro experiments (Fig. 1) .
To independently quantify the biological impact of ANP-BNP interaction, we examined IAV growth in modified MDCK cell lines stably expressing either wild-type or non-interacting mutant BNPs (E395A, F468S, R472A) (Fig. 4C) . Western blotting confirmed similar expression of all BNP variants (Fig. 4D) . Notably, these MDCK cell lines expressed much higher levels of BNP proteins compared to the MDCK-BNP cell line used in previous work, possibly due to the efficiency of lentiviral transduction (data not shown; Wanitchang et al., 2012) . For viral growth kinetics analysis, supernatants from PR8-infected MDCK cells and those harboring each of the BNP variants (MOI ¼0.001) were harvested at 12 and 24 h post-infection and assessed for viral titers in fresh MDCK cells. The viruses retrieved from MDCK, MDCK-BNP F468S, and MDCK-BNP R472A cells grew to equivalent titers (Fig. 4D) . Remarkably, we observed large growth retardation ( $ five-log) in MDCK-BNP cells, whereas intermediate growth delay was observed in MDCK-BNP E395A cells (Fig. 4D) .
Interestingly, the viral growth inhibitory effect observed with MDCK-BNP cells was much more pronounced than that observed in the case of ΔPB2-PR8-BNP virus (cf. Fig. 4D and B). We suspected that this discrepancy might stem from unequal BNP expression between the two systems. Indeed, we observed noticeably larger BNP expression in the cell lines than in cells infected with the chimeric viruses (Fig. 4E, ' cl' vs. 'cv' lanes). In the case of wild-type BNP, comparing expression levels in these conditions might have been complicated by BNP's own inhibitory effect on the ΔPB2-PR8-BNP virus, as a faint band for ANP could only be observed upon long exposure (data not shown). Nevertheless, we could infer difference in expression levels from BNP mutants which have negligible effects on viral growth in either system (Fig. 4E, F468S and R472A). It is conceivable that timing of BNP expression might also contribute to the discrepancy. In the case of chimeric viruses, BNP expression is initiated only upon primary transcription by the incoming viruses, whereas BNP is already present in the MDCK-BNP cell line prior to infection. Overall, the data in this part implied that BNP expression levels, and also perhaps its timing, are critical for its IAV inhibitory effect, once again arguing for the competitive nature of the inhibition mechanism. Notably, these results also proved that BNP was capable of enormous viral growth suppression upon a suitable expression level, showcasing its potency as a strong antiviral protein.
ANP reciprocally engages BNP via its oligomerization motifs
We reciprocally identified the ANP motifs necessary for intertypic NP complex formation. To this end, we generated ANP-R416A and ANP-E339A, the reciprocal tail loop and tail-loop receptor mutants, and tested their ability to bind BNP. HEK293T cells were co-transfected with plasmids expressing Myc-tagged BNP and each of the ANP variants. Co-immunoprecipitation with anti-Myc antibody showed impairment in BNP binding by both ANP mutants compared to wild-type ANP (Fig. 5A) . In a similar setting, ANP-Myc indistinguishably pulled down all ANP variants (wildtype, E339A or R416A), suggesting that, at least, the binary complexes between ANP-Myc and these ANP mutants could be detected by our co-immunoprecipitation conditions ( Supplementary Fig. 1 ). This pattern is in stark contrast to severe loss of ANP mutants in the complex pulled down by BNP-Myc, suggesting that these ANP mutants could not bind BNP-Myc. The results in this section suggested that ANP's homo-oligomerization motifs are necessary for intertypic NP interaction.
Other mutations that could essentially lock ANP in either the monomeric or oligomeric states have been reported (Chenavas et al., 2013) . A phosphorylation site mutation (S165D) abolishes ANP oligomerization by precluding proper tail loop-tail-loop receptor interactions (Chenavas et al., 2013; Turrell et al., 2015; Mondal et al., 2015) . On the other hand, ANP-Y148A exists predominantly in an oligomeric state in biochemical characterization (Tarus et al., 2012) . Its cellular state, oligomerization dynamics and biological significance are unclear, but the recombinant virus harboring this mutation could not be rescued (Li et al., 2009) . To test how oligomeric states of ANP affect BNP binding, we performed co-immunoprecipitation with antiMyc antibody on lysates containing Myc-tagged BNP and each of these ANP variants. The obligatory monomeric ANP-S165D was barely visible in co-IP elution, whereas the ultra-stable oligomeric ANP-Y148A could be captured slightly less compared to wild-type ANP (Fig. 5B) . These results suggest that oligomerization dynamics is important to both intertypic and homotypic oligomerization. Alternatively, S165 or phosphorylation of ANP might directly mediate intertypic interactions.
ANP utilizes distinct residues in binding to BNP and PB2
Previously, we proposed a model in which BNP's interaction with ANP interferes with vRNP complex formation. In the presence of all polymerase subunits, we showed that increasing BNP results in diminishing polymerase subunits (PB2) co-precipitating with ANP (Jaru-ampornpan et al., 2014) . However, it is not known whether BNP could disrupt the pairwise ANP-PB2 interaction. Furthermore, does BNP also interrupt ANP's interaction with other polymerase subunits? To this end, we co-expressed ANP with either FLAG-tagged PB1 or PB2, the two IAV polymerase subunits reported to bind ANP (Biswas et al., 1998) , in the presence of increasing BNP and performed co-immunoprecipitation using anti-ANP antibody. The amount of PB2-FLAG in the co-IP complex was correspondingly diminished upon increasing BNP, as previously observed in the context of a complete polymerase complex ( Fig. 6A and C) . In contrast, the amount of PB1-FLAG pulled down by ANP did not significantly change in the presence of increasing BNP (Fig. 6B and C) . These results suggested that BNP specifically disrupts ANP-PB2 interaction even without other vRNP subunits but does not interfere with PB1 binding.
To test if BNP competes with PB2 for the same interaction sites on ANP, which is the simplest model of interference, we studied ANP mutants previously characterized for polymerase binding (Marklund et al., 2012; Gui et al., 2014) . We verified these mutants' effects on ANP-PB2 interaction in our experimental conditions and found that D88A and WR207,208AA showed severe and moderate loss in PB2 binding, respectively ( Fig. 6D and F) . Coimmunoprecipitation of the lysates containing Myc-tagged BNP and each of the ANP variants (wild-type, D88A and WR207,208AA) with anti-Myc antibody revealed no drastic difference in the amount of the co-eluted ANP ( Fig. 6E and F) . It is arguable that ANP-D88A might bind BNP-Myc slightly less well, but this small decrease did not reflect the severe loss of PB2 binding exhibited by this mutant in our experimental conditions (Fig. 6F) . These results implied that ANP utilizes distinct interaction sites to bind BNP and PB2.
BNP's antiviral effect is specific to IAV but can vary over different strains
We next asked how other IAV strains respond to BNP. To this end, we repeated the experiments with additional strains: A/ Uruguay/716/2007 (H3N2) and A/duck/Suphanburi/AI157/2005 (H6N1). Co-immunoprecipitation showed that Myc-tagged ANP derived from each strain could bind to BNP, but efficiency of the intertypic NP interactions seemed slightly varied (Fig. 7A) . Next, using the minigenome assay, we showed that both H3N2 and H6N1 polymerases showed substantial reduction in their activities in the presence of BNP (Fig. 7B) . Although still quite efficient, inhibition observed with H3N2 polymerase was smaller than those observed with H1N1 and H6N1 polymerases. To examine growth suppression by BNP, MDCK and MDCK-BNP cells were infected with each strain (MOI ¼0.001), and viral progenies were assessed by plaque assay. Growth suppression of H3N2 was less pronounced than that of H1N1, consistent with the in vitro results from polymerase inhibition (Fig. 7C) . These results suggested that BNP has a potential to broadly suppress several IAV strains, albeit with different efficiency.
Lastly, to demonstrate specificity of BNP's inhibitory effect, we tested if BNP could stall growth of other RNA viruses. We infected MDCK and MDCK-BNP cells with vesicular stomatitis virus (VSV; MOI¼ 0.001) and compared VSV replication in these cells. VSV could efficiently replicate in MDCK cells, acquiring reasonable titers at 10 4 PFU/ml after 12 h (Fig. 7D) . VSV grew equally well in MDCK-BNP cells, showing no sign of growth inhibition (Fig. 7D) . These results suggested that BNP's antiviral effect is not generalized.
Discussion
One of the long-standing observations about intertypic interference is suppression of IAV growth upon co-infection with IBV (Tobita and Ohori, 1979; Mikheeva and Ghendon, 1982; Kaverin et al., 1983; Aoki et al., 1984; Wanitchang et al., 2012) . In our previous publications, we proposed a model in which BNP mediates IAV growth suppression via interaction with ANP and disruption of IAV vRNP complex formation (Wanitchang et al., 2012; Jaruampornpan et al., 2014) . As a continuation, we here characterized molecular interactions mediating this detrimental ANP-BNP intertypic interaction and investigated how it disrupts the essential interactions between ANP and individual polymerase subunits.
In this work, we confirmed that the homo-oligomerization property of BNP is critical for BNP's inhibitory effect on IAV because the same motifs also mediate heterotypic oligomer formation. Early study with the tail-loop truncation mutant suggested that the tail loop was involved in BNP's inhibitory action. However, very low expression of this mutant created rooms for alternative explanations that the lack of IAV polymerase inhibition might have stemmed from structural and expression concerns (Wanitchang et al., 2012) . In this work, we ruled out these possibilities by studying point mutations on the tail loop that have been specifically described for homo-oligomerization (Ng et al., 2012) . These BNP mutants revealed loss in ANP interaction, severe defects in IAV polymerase inhibition and no suppression on IAV growth. Reciprocally, ANP homo-oligomerization mutants displayed lack of intertypic NP interaction. Additionally, we used help from the BNP crystal structure to generate several mutations on the tail-loop receptor side and showed that the ability to interrupt IAV polymerase activity correlates well with intertypic NP complex formation. These data together suggest that the tail loop and the tail-loop receptor areas of BNP are necessary for IAV polymerase inhibition most likely because they are involved in formation of ANP-BNP heterotypic complex through a similar mechanism as homotypic oligomers.
A few observations from our mutagenesis study are worth noting. First, BNP-E395A showed no ANP binding in our coimmunoprecipitation experiment but displayed residual inhibitory effects on IAV polymerase and growth suppression. From our collection of twelve BNP mutants, this is the only outlier to the correlation between IAV polymerase inhibition and ANP interaction. Although we could not completely rule out other possibilities, we are inclined to believe that transient or weak interactions between ANP and BNP-E395A might evade detection by our current assay, but the inhibition mechanism proceeds identically to wild-type BNP albeit with much lower efficiency. First, the inhibition profile of BNP-E395A displays the same competitive behavior as wild-type, potentially reaching the same level of inhibition but with a much higher effective concentration to reach 50% inhibition (Fig. 1E) . Simplistically, this is a proxy for difference in binding affinity between the two competitors (wild-type vs. E395A). Second, a recent report has suggested that the equivalent mutation in ANP, E339A, acted as a dominant negative in vRNP formation, indicating that ANP-E339A could be incorporated to terminate the NP chain but could not function (Turrell et al., 2013) . Likewise, it could be envisioned that BNP-E395A might be incorporated to terminate the intertypic NP chain, and the effect of this binding is only manifested in a polymerase inhibition assay which might be more sensitive than co-immunoprecipitation in this case. Another interesting mutation is BNP-R447A, which could inhibit IAV polymerase but could not support IBV polymerase. This is an example case that decouples BNP's functionality from its capacity to suppress IAV replication and helps refine our earlier conclusion Fig. 6 . BNP disrupts ANP-PB2 interaction but not ANP-PB1 interaction. HEK293T cells were co-transfected (500 ng each) with pHW2000-ANP and pHW2000-PB2-FLAG (A) or pHW2000-PB1-FLAG (B) in the absence or presence of pHW2000-BNP (amount as indicated). Cell lysates were subjected to co-IP by anti-ANP antibody and analyzed by western blots with indicated antibodies. (C) Quantification of PB2-FLAG or PB1-FLAG pulled down by ANP. For each IP reaction, the 'prey' band (anti-FLAG) was normalized by the corresponding 'bait' band (anti-ANP) from the same lane. Values are displayed relative to those in the 'no BNP' conditions. HEK293T cells were cotransfected (500 ng each) with pHW2000-ANP (WT, D88A or WR207,208AA) and pHW2000-PB2-FLAG (D) or pHW2000-BNP-Myc (E). Cell lysates were subjected to co-IP by anti-ANP (D) or anti-Myc (E) antibody and analyzed by western blots with indicated antibodies. (F) Quantification of PB2-FLAG or ANP pulled down by ANP or BNP-Myc, respectively. The 'prey' bands (anti-FLAG or anti-ANP) were normalized by their corresponding 'bait' bands (anti-ANP or anti-Myc) from the same lane. Values are displayed relative to those in the 'WT' conditions. drawn from studying truncation mutants (Wanitchang et al., 2012) . Rather than being full-length and functional, BNP only needs to correctly localize and bind ANP to suppress IAV polymerase activity. Also supporting this notion are the phosphomimetic BNP mutants, BNP-S226D and BNP-S463D, that could not support IBV polymerase function but were able to efficiently suppress IAV polymerase activity. Curiously, they cannot selfassociate but are able to bind ANP (Mondal et al., 2015 and Fig. 3C ). Note that this pattern is in contrast to the phosphomimetic ANP mutant which could not retain BNP binding, possibly suggesting directionality or asymmetry in heterotypic NP complex formation. These data also imply that there exist small but important differences in molecular details between the homotypic and heterotypic nucleoprotein complexes, although the main oligomerization motifs are similarly utilized in both. Nevertheless, higher-resolution structural information from the heterotypic NP complex is necessary to confirm these conjectures.
How could the heterotypic NP complex interfere with IAV polymerase? We showed here that, in the absence of other polymerase subunits, BNP disrupts essential interaction between ANP and PB2 but does not interfere with PB1. However, ANP mutants that are defective in polymerase binding showed minimal effects on BNP binding. These data together suggested that BNP could interfere with the ANP-PB2 complex by sequestering ANP from PB2, but the ANP-BNP binding interface does not entirely overlap with the ANP-PB2 binding interface. Although characterization of the complete NP-polymerase binding interfaces is still pending, these data argue for an alternative inhibition model in which BNP binding possibly causes structural or conformational changes on ANP that prohibit PB2 binding. Furthermore, co-immunoprecipitation shows that BNP cannot interact with IAV's PB2 (Jaru-ampornpan et al., 2014) . Therefore, despite the closeness in the assembly mechanism or the gross structures of these nucleoprotein complexes, the intertypic NP complexes could not functionally replace the homotypic ANP complexes and would result in decreases in IAV replication.
Our study of the BNP's anti-IAV effect using several approaches has revealed subtlety in BNP-mediated IAV inhibition mechanism as well as achievable potency of BNP. IAVs replicated 10 5 times less efficiently in MDCK-BNP cells, in which BNP protein is available at a substantial level prior to infection. However, the effect of BNP on growth kinetics of the chimeric ΔPB2-PR8-BNP viruses was appreciably masked, supposedly due to two critical factors: BNP timing and expression levels relative to ANP. While the incoming ΔPB2-PR8-BNP chimeric viruses carry functional polymerase complexes and numerous copies of ANP, they do not package BNP protein into the particles (data not shown), already putting them at a disadvantage both in terms of timing and amount of BNP. Compared to BNP expression in MDCK-BNP cells (under the SFFV promoter), BNP expression under the PR8 PB2 UTR is noticeably smaller (Fig. 4E) . Therefore, in the case of infection by chimeric viruses, the much greater amount of ANP produced under its native UTR during the replication cycle will eventually overwhelm BNP. Taken together, these results demonstrated that timing and expression level of BNP could profoundly affect its anti-IAV property. These data are also consistent with previous work which demonstrated that a large amount of ANP could reverse BNP's inhibitory effect and that IBV could no longer suppress IAV replication if IAV infection was established at least two hours prior to IBV infection (Wanitchang et al., 2012) . Notably, the observation that BNP's antiviral effect is intimately dependent on its expression level is a hallmark of a competitive nature of the proposed inhibition mechanism. Nevertheless, during co-infection, other mechanisms besides BNP's inhibitory effect on IAV polymerase could contribute to intertypic interference (Mikheeva and Ghendon, 1982; Aoki et al., 1984; Muster et al., 1991; Baker et al., 2014; Iwatsuki-Horimoto et al., 2008; Wunderlich et al., 2010) . Although attractive, this proposed mechanism might not recapitulate every aspect of BNP's inhibitory effect. Especially, the effect of BNP on the H3N2 virus is interesting. Co-immunoprecipitation showed that ANP from H3N2 could bind to BNP, albeit slightly less efficiently. Nevertheless, we could observe a sizable relief in BNP's inhibitory effect toward H3N2 polymerase and its growth. These data might hint at contributions from other viral factors, especially the polymerase subunits, that may modulate the inhibitory effect of BNP. In addition, nucleoprotein interacts with a myriad of host proteins as well as other viral proteins during the viral life cycle (Portela and Digard, 2002) , opening up possibilities for modulation of BNP's inhibition.
In conclusion, we have provided additional mechanistic details regarding BNP-mediated IAV polymerase inhibition and demonstrated the antiviral effect of BNP. As shown in this report, IAV growth suppression exhibited by BNP could be substantial upon appropriate timing and expression level. In line with the proposed mechanism of action, BNP's inhibitory effect is specific to IAVs and could vary in degree upon the identity of the tested IAV strains. More investigation is underway to assess the potential of developing BNP, or parts of the protein, into a novel potent and broad-spectrum anti-IAV agent. On the other hand, lessons from molecular study of BNP's viral suppression mechanism like this work could benefit the design of novel antiviral small molecules targeting ANP.
Materials and methods
Biological materials
Construction of plasmids expressing tagged proteins was described previously (Jaru-ampornpan et al., 2014) . Point mutations in ANP and BNP were constructed by PCR-based site-directed mutagenesis. The following antibodies were used according to the manufacturer's recommendations: anti-ANP and anti-BNP (South- 
Co-immunoprecipitation (co-IP)
Co-immunoprecipitation was performed as described previously (Jaru-ampornpan et al., 2014) . In brief, HEK293T cells were transfected with indicated plasmids (500 ng each, unless otherwise specified). Cells were lysed at 48 h post-transfection with co-IP buffer [50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM EDTA, 1% NP-40 supplemented with protease inhibitor cocktail (SigmaAldrich)]. Clarified lysates were incubated with agarose beads conjugated with primary antibodies (Thermo Scientific). The IP complex was washed three times in co-IP buffer supplemented with 250 mM NaCl, eluted by boiling the beads in SDS-PAGE gel loading buffer, and analyzed by Western blotting. Co-IP negative controls using mouse IgG coupled to agarose beads showed no bands for both bait and prey proteins in elution for all the interaction pairs tested in this study (Supplementary Fig. 1 ).
Figures are representative of three independent experiments. Direct comparisons in the same panels were performed in sideby-side experiments. Quantification of co-IP bands was performed with ImageJ (Schneider et al., 2012) and represents average7S.D. from three independent experiments.
Minigenome assay
The IAV and IBV minigenome assays were performed as previously described (Wanitchang et al., 2012) . Briefly, HEK293T cells were transfected with a set of plasmids expressing PB2, PB1, PA, NP, and an RNA polymerase I-driven plasmid expressing negative-sense viral RNA encoding secreted neuraminidase to reconstitute IAV or IBV vRNPs. Polymerase activity was determined by quantification of neuraminidase activity to convert 2 0 -(4-Methylumbelliferyl)-α-D-N-acetylneuraminic acid (Sigma-Aldrich) to a fluorescent product (Potier et al., 1979) . In IAV inhibition experiments, plasmids expressing BNP variants were cotransfected to determine their ability to suppress expression of the neuraminidase gene. Values are expressed relative to IAV polymerase activity in the absence of BNP and are averages7S. D. from three independent experiments.
Immunofluorescence
HEK293T cells were seeded on chamber slides and transfected with plasmids expressing Myc-tagged BNP variants. At 16 h posttransfection, cells were fixed and permeabilized with 100% icecold acetone for 5 min and blocked with phosphate-buffered saline (PBS) supplemented with 1% bovine serum albumin (BSA) and 10% FBS. After 1-h incubation with anti-Myc antibody, permeabilized cells were washed with PBS supplemented with 0.05% tween-20. FITC-conjugated goat-anti-mouse IgG was then added. After five washes, the fluorescence images were taken on fluorescence microscope (Olympus). Nuclei were stained with DAPI.
Construction of MDCK cell lines expressing influenza viral proteins
To construct lentiviral vectors expressing influenza virus proteins, IAV PB2 or BNP genes were amplified from pHW2000-based plasmids. The PCR products were digested and inserted into BamHI and XhoI sites of the pSIN-CSGW-UbEm lentivitral vector. Expression of influenza virus genes was driven by the spleen focus-forming virus (SFFV) promoter. The lentiviruses encoding influenza virus proteins were recovered based on the method described previously (Schmeckpeper et al., 2009) . Briefly, HEK293T cells were transfected with lentiviral vectors in combination with a packaging plasmid (pCMV-ΔR8.91 encoding the packaging proteins Gag-Pol, Rev, Tat) and an envelope expression plasmid (pMD.G encoding the VSV glycoprotein). Viral supernatant was harvested at 48 h and filtered through a 0.45 μm filter. Subsequently, the lentiviruses were transduced into MDCK cells. Single clones of MDCK cells expressing influenza viral proteins were identified and selected from the population pool based on emerald fluorescence intensity by FACS analysis (BD FACSAria II, BD Biosciences). For MDCK-BNP series, clones were further selected based on similar expression of BNP variants ( Supplementary Fig. 2 ).
Reverse genetics of mCherry-or BNP-expressing influenza viruses
Reverse genetics of recombinant IAV harboring mCherry or BNP in place of the original PB2 segment was carried out with bidirectional pHW2000 plasmids containing the cDNAs of PR8 genes. Briefly, the pHW2000-PB2 plasmid was first modified to contain variants of BNPs or mCherry flanked by PB2 3 0 -and 5 0 -UTRs including putative packaging signals (120 nucleotides of the coding sequence at the 3 0 end and 336 nucleotides of the coding sequence of the 5 0 end) (Uraki et al., 2013) . The resulting plasmids were designated pPB2(120)BNP(336) or pPB2(120)mCherry(336). To generate recombinant IAV, pPB2(120)BNP(336) or pPB2(120) mCherry(336) was mixed with pHW2000 plasmids expressing PB1, PA, HA, NP, NA, M and NS genes (500 ng each). In addition, pCAGGS expressing PB2 (1 μg) was included in the plasmid mixture. The combined plasmids were transfected into HEK293T-MDCK-PB2 co-culture. At 24 h post-transfection, TPCK-trypsin (2 μg/ml) was added to the supernatant. At 72 h post-transfection, supernatants containing recombinant IAV were harvested and further propagated in MDCK-PB2 cells.
Viral growth analysis
MDCK cells were infected with each virus strain at 0.001 multiple of infectivity (MOI). One h post-adsorption, the cells were washed once with PBS, and 2 ml of fresh Opti-MEM containing 2 μg/ml TPCK-trypsin was added to each well. The supernatant was collected at indicated time points post-infection for virus titration by plaque assay. For plaque assay, monolayers of MDCK cells (or MDCK-PB2 cells for Fig. 4B ) were adsorbed for 1 h with 1 ml of 10-fold serially diluted virus. After removal of inocula, the cells were washed with PBS and covered with 3 ml of agar media (0.9% Bacto-agar, 1 Â MEM, 20 mg/ml BSA, 0.225 mg/ml sodium bicarbonate and 2 μg/ml TPCK-trypsin). After 72-h incubation at 37 1C, the agar mix was removed and the cells were stained with a 0.1% crystal violet solution. Plaques were counted, and the numbers reported are averages of three independent experiments.
